+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Secondary analysis of economic data: a review of cost-benefit studies of neonatal screening for phenylketonuria



Secondary analysis of economic data: a review of cost-benefit studies of neonatal screening for phenylketonuria



Journal of Epidemiology and Community Health 53(3): 179-186



To estimate the net financial benefit of neonatal screening for phenylketonuria (PKU): by a simple pooling of cost data from the literature; and by a more complex modelling approach. A systematic literature review was conducted to identify papers containing data on the monetary costs and benefits of neonatal screening for PKU. The methodological quality of the studies was appraised, and data were extracted on resource use and expenditure. Monetary data were converted to common currency units, and standardised to UK incidence rates. Net benefits were calculated for median, best case and worst case scenarios, and the effect of excluding poor quality studies and data was tested. The net benefit was also estimated from a model based on data from the literature and assumptions appropriate for the current UK situation. Extensive sensitivity analysis was conducted. The direct net benefit of screening based on the median costs and benefits from the 13 studies identified was 143,400 Pounds per case detected and treated (39,000 Pounds and 241,800 Pounds for worst case and best case scenarios respectively). The direct net benefit obtained by the modelling approach was lower at 93,400 Pounds per case detected and treated. Screening remained cost saving under sensitivity analysis, except with low residential care costs (less than 12,300 Pounds per annum), or very low incidence rates (less than 1 in 27,000). The economic literature on PKU screening is of variable quality. The two methods of secondary analysis lead to the same conclusion: that neonatal PKU screening is worthwhile in financial terms alone in the UK, and that it justifies the infrastructure for collecting and testing neonatal blood samples. This result cannot necessarily be extrapolated to other countries.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 047320432

Download citation: RISBibTeXText

PMID: 10396496

DOI: 10.1136/jech.53.3.179


Related references

Secondary Analysis of Economic Data: A Review of Cost-Benefit Studies of Neonatal Screening for Phenylketonuria. Journal of Epidemiology and Community Health (1979-) 53(3): 179-186, 1999

Economic evaluation of cost-benefit ratio of neonatal screening procedure for phenylketonuria and hypothyroidism. Journal of Inherited Metabolic Disease 14(4): 633-639, 1991

A cost-benefit evaluation of neonatal screening for phenylketonuria and congenital hypothyroidism. Zhonghua Yu Fang Yi Xue Za Zhi 34(3): 147-149, 2000

Ultrasound screening of the neonatal hip: cost-benefit analysis. Croatian Medical Journal 42(2): 171-174, 2001

Cost/benefit study of the neonatal detection of phenylketonuria and hypothyroidism. Pediatrie 43(4): 345-348, 1988

Economic analysis and public health. Why does one need economic evaluation applied to diabetes? What methods does one choose: cost effectiveness, cost utility, cost benefit? Are such studies useful in terms of public health?. Diabete and Metabolisme 19(5 Suppl): 473-476, 1993

Economic analysis and public health: Why do we need economic evaluation applied to diabetes? What methods must we choose: Cost-effectiveness, cost-utility, cost-benefit? Are such studies useful in terms of public health?. Diabete & Metabolisme 19(5 Suppl. ): 473-476, 1993

Economic Benefit-Cost Analysis of Select Secondary Prevention Interventions in LMIC. Global Heart 10(4): 319-321, 2015

Benefit of neonatal screening for phenylketonuria. A report of the first case treated in China. Chinese Medical Journal 99(6): 513-514, 1986

A cost-benefit analysis of screening and prophylaxis for serodiscordant couples to prevent neonatal herpes. International Journal of STD & AIDS 12(Suppl. 2): 169-170, 2001

Economic evaluation of neonatal screening for phenylketonuria and congenital hypothyroidism. Journal of Paediatrics and Child Health 41(11): 575-579, 2005

Cost effectiveness of establishing a neonatal screening programme for phenylketonuria in Libya. Applied Health Economics and Health Policy 8(6): 407-420, 2010

Cost-benefit analysis of mammography screening in Denmark based on discrete ranking data. International Journal of Technology Assessment in Health Care 16(3): 811-821, 2000

Economic evaluation of telemedicine: review of the literature and research guidelines for benefit-cost analysis. Telemedicine Journal and E-Health 15(10): 933-948, 2009

Health economic studies: an introduction to cost-benefit, cost-effectiveness, and cost-utility analyses. Spine 39(22 Suppl 1): S9, 2014